Obsessive compulsive disorder and the glutamatergic system.

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Current pharmacological treatments for obsessive compulsive disorder (OCD) primarily target serotonergic and dopaminergic pathways.
• These established treatments are not universally effective, necessitating exploration of novel therapeutic targets.

Purpose of the Study:

• To review emerging evidence on the role of the glutamatergic system in OCD.
• To assess the potential of glutamatergic pathways as targets for novel OCD pharmacotherapies.

Main Methods:

• Review of animal models and clinical research, including brain imaging and genetics.
• Analysis of existing studies on glutamatergic agents in OCD.

Main Results:

• Growing evidence from preclinical and clinical studies supports the glutamatergic system as a viable target for OCD pharmacotherapy.
• Several glutamatergic agents, including riluzole, memantine, ketamine, topiramate, lamotrigine, N-acetylcysteine, and D-cycloserine, have shown preliminary promise.
• Limited randomized controlled trials exist for these agents in pediatric and adult OCD populations.

Conclusions:

• The glutamatergic system presents a significant opportunity for developing more effective OCD treatments.
• Further research and clinical trials are crucial to evaluate glutamatergic agents as standalone, augmentation, or adjunctive therapies for OCD.